The sudden outbreak of coronavirus turned into a pandemic and resulted in huge socio-economic and human losses becoming a public health emergency. It took just 3-4 months to spread and encroach all over the world and not even a single country is left was unaffected by the coronavirus. WHO started clinical, epidemiological, and laboratory investigations in response to this outbreak to control the further spread of the virus. The coronaviruses are enveloped and pleomorphic. The spike proteins present on the virus surface mediate its entry into host cells. The vaccines recommended have been shown to reduce COVID-19 illness symptoms but somehow their role in the transmission of the disease is unclear. By contrast, immunomodulatory therapy has also benefitted patients. As long as SARS-CoV-2 spreads in the population there are chances of its mutation as RNA viruses mutate over time and its upcoming variants. The previous Delta variant and the latest Omicron variant may cause much more serious deaths and health issues. Variants reduce the effectiveness of monoclonal antibodies or antibodies generated by previously administered vaccines. This review focuses on the pathogenicity of coronavirus and various drug therapies available to date to cure the disease. The present study also highlights the target sites and side effects of available drugs for treating COVID-19.
This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit: http://creativecommons.org/licenses/by/4.0/
CMBR journal remains neutral with regard to jurisdictional claims in published maps and institutional afflictions.
Letters to Editor
Given that CMBR Journal's policy in accepting articles will be strict and will do its best to ensure that in addition to having the highest quality published articles, the published articles should have the least similarity (maximum 18%). Also, all the figures and tables in the article must be original and the copyright permission of images must be prepared by authors. However, some articles may have flaws and have passed the journal filter, which dear authors may find fault with. Therefore, the editor of the journal asks the authors, if they see an error in the published articles of the journal, to email the article information along with the documents to the journal office.
CMBR Journal welcomes letters to the editor ([email protected]) for the post-publication discussions and corrections which allows debate post publication on its site, through the Letters to Editor. Critical letters can be sent to the journal editor as soon as the article is online. Following points are to be considering before sending the letters (comments) to the editor.
 Letters that include statements of statistics, facts, research, or theories should include appropriate references, although more than three are discouraged.
 Letters that are personal attacks on an author rather than thoughtful criticism of the author’s ideas will not be considered for publication.
 There is no limit to the number of words in a letter.
 Letter writers should include a statement at the beginning of the letter stating that it is being submitted either for publication or not.
 Anonymous letters will not be considered.
 Letter writers must include Name, Email Address, Affiliation, mobile phone number, and Comments
 Letters will be answered as soon as possible